Travere Therapeutics won full FDA approval for Filspari (sparsentan) in focal segmental glomerulosclerosis (FSGS), completing the company’s path from earlier accelerated clearances. The new regulatory label expands a market opportunity and validates proteinuria reduction as a surrogate endpoint for this rare kidney disease. The approval extends Filspari beyond its prior indications and reframes proteinuria as a measurable readout that can support additional rare-disease approvals. For nephrology-focused developers, the decision also reinforces the evidentiary pathway used to move from accelerated to full approval. Analysts cited in the reporting project meaningful peak sales potential from the FSGS and prior IgA nephropathy (IgAN) labels, which could drive further investment in complementary agents targeting glomerular pathways. The approval lands as competitors vie for position in proteinuria-driven treatment areas, making it a regulatory and commercial milestone for Travere’s platform-oriented strategy.